Literature DB >> 29770812

Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery.

Ming Wu1, Jiong Li, Xinyi Lin, Zuwu Wei, Da Zhang, Bixing Zhao, Xiaolong Liu, Jingfeng Liu.   

Abstract

Dual and multi-stimuli responsive polymeric nanoparticles that respond to two or more signals can further improve drug release performance compared with nanoparticles that respond to a single stimulus. However, usage of such nanoparticles to deliver siRNA and chemotherapeutic drugs in a sequential manner are currently very rare; meanwhile, this technology is vital to optimize the efficacy of chemotherapy towards cancer cells with multidrug resistance. By loading o-nitrobenzyl ester derivative caged DOX (DOC) into the inner poly(lactic-co-glycolic acid) (PLGA) core and adsorbing siRNA of P-gp protein onto the cationic polymeric shell derived from a disulfide-containing alkyl modified polyethylenimine (C16-S-S-PEI), here, a reduction/photo dual responsive device (RPDRD) is successfully designed for programmed P-gp siRNA and doxorubicin delivery. The dual-stimuli design of the RPDRD allows tumor microenvironment-specific and rapid release of P-gp siRNA triggered by the enrichment of reducing agent glutathione (GSH, up to 10 mM) for reversal of drug resistance by initially suppressing P-gp protein expression in MCF/ADR cells and then selectively triggering drug release by external light for chemotherapy afterwards. The sequential release behavior of P-gp siRNA and DOX can be demonstrated both in vitro and in vivo, thus enhancing the intracellular drug retention and optimizing the chemotherapy efficacy of DOX by silencing P-gp; this strategy may have extensive application prospects in MDR cancer treatment in future.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29770812     DOI: 10.1039/c8bm00226f

Source DB:  PubMed          Journal:  Biomater Sci        ISSN: 2047-4830            Impact factor:   6.843


  7 in total

1.  Tumor Microenvironment Stimuli-Responsive Polymeric Prodrug Micelles for Improved Cancer Therapy.

Authors:  Zhiqiang Zhang; Miao Yu; Tong An; Jun Yang; Meijuan Zou; Yinglei Zhai; Wei Sun; Gang Cheng
Journal:  Pharm Res       Date:  2019-12-10       Impact factor: 4.200

2.  Disulfide Bridging Strategies in Viral and Nonviral Platforms for Nucleic Acid Delivery.

Authors:  Kingshuk Dutta; Ritam Das; Jewel Medeiros; S Thayumanavan
Journal:  Biochemistry       Date:  2021-01-11       Impact factor: 3.162

Review 3.  Disulfide based prodrugs for cancer therapy.

Authors:  Qiang Wang; Jiankun Guan; Jiangling Wan; Zifu Li
Journal:  RSC Adv       Date:  2020-06-25       Impact factor: 4.036

Review 4.  Recent Trends in Nanomedicine-Based Strategies to Overcome Multidrug Resistance in Tumors.

Authors:  Muhammad Muzamil Khan; Vladimir P Torchilin
Journal:  Cancers (Basel)       Date:  2022-08-26       Impact factor: 6.575

5.  Conjugation of Doxorubicin to siRNA Through Disulfide-based Self-immolative Linkers.

Authors:  Florian Gauthier; Jean-Rémi Bertrand; Jean-Jacques Vasseur; Christelle Dupouy; Françoise Debart
Journal:  Molecules       Date:  2020-06-11       Impact factor: 4.411

6.  Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Kiavash Hushmandi; Farid Hashemi; Ebrahim Rahmani Moghadam; Mehdi Raei; Mahshad Kalantari; Shima Tavakol; Reza Mohammadinejad; Masoud Najafi; Franklin R Tay; Pooyan Makvandi
Journal:  ACS Comb Sci       Date:  2020-10-23       Impact factor: 3.784

Review 7.  Near-infrared light-triggered nano-prodrug for cancer gas therapy.

Authors:  Runcong Liu; Yongjun Peng; Ligong Lu; Shaojun Peng; Tianfeng Chen; Meixiao Zhan
Journal:  J Nanobiotechnology       Date:  2021-12-23       Impact factor: 10.435

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.